ArticleResearch in pharmaceutical sciences2026
Investigating the
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Natural compounds combined with human adipose-derived stem cell (hADSCs) transplantation could be considered an effective treatment for multiple sclerosis (MS). In the present study, the effects of bromelain administration in combination with hADSCs transplantation were evaluated for oligodendrocyte differentiation, myelin tissue regeneration, and improvement of motor function. Experimental approach: After inducing an MS mouse model, the mice were randomly divided into 4 groups: MS, MS + bromelain, MS + stem cell, and MS + bromelain + stem cell. Besides, 16 mice were designated for the control and sham groups. Finally, the behavioral test is used to evaluate motor function and motor defects. Furthermore, immunofluorescent staining was used to evaluate the cell markers. The serum levels of IgG, as well as inflammatory and anti-inflammatory factors, were assessed using an ELISA test. Findings/Results: The mean percentages of Olig2- and Mog-positive cells, myelin density, and the serum levels of IL-10 and TGF-β were significantly higher in the treated groups than in the MS group. However, the serum levels of IL-17 and IFN-γ in the MS group were significantly higher compared to the other groups. Also, the serum level of IgG in the MS group was significantly higher than in the other groups. Conclusion and implications: It can be said that hADSCs transplantation, along with bromelain administration, is able to increase myelination and improve balance function. Therefore, the use of these agents could be a fundamental step towards finding a suitable method for the treatment of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.